Thomas Gad - 23 Nov 2021 Form 4 Insider Report for Y-mAbs Therapeutics, Inc. (YMAB)

Role
Chairman, President and Head of Business Development & Strategy, Director
Signature
/s/ THOMAS GAD
Issuer symbol
YMAB
Transactions as of
23 Nov 2021
Transactions value $
-$752,850
Form type
4
Filing time
26 Nov 2021, 16:33:22 UTC
Previous filing
18 Nov 2021
Next filing
01 Dec 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction YMAB Common Stock Options Exercise $100,000 +50,000 +100% $2 100,000 23 Nov 2021 Direct
transaction YMAB Common Stock Sale -$852,850 -50,000 -50% $17.06 50,000 23 Nov 2021 Direct F1
holding YMAB Common Stock 1,484,927 23 Nov 2021 By GAD Enterprises LLC F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction YMAB Employee Stock Option (right to buy) Options Exercise $0 -50,000 -22.83% $0 169,000 23 Nov 2021 Common Stock 50,000 $2 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was executed in multiple trades at prices ranging from $16.4300 to $17.4450. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F2 Reporting Person is sole member of GAD Enterprises, LLC and the sole member and manager of GAD Management, LLC, the manager of GAD Enterprises, LLC, and as such Reporting Person has sole voting and dispositive power with respect to such shares.
F3 The stock option vested and became exercisable as to 25% of the shares subject to the option on June 10, 2016, and thereafter vested as to 1/48th of the shares in equal monthly installments, until such time as the option was 100% vested on June 10, 2019.

Remarks:

Chairman, President and Head of Business Development & Strategy